We have identified (I) reduced HIF-1α gene expression and protein levels in isolated PBMCs from HHT patients, (II) reduced HIF-1α target gene expression of genes related to metabolism, (III) impaired metabolic capacity of HHT PBMCs, and (IV) the possibility of enhancing metabolism by pharmacological HIF-1α stabilization. The gene discussed is HIF1A; the disease is hereditary hemorrhagic telangiectasia.